Overview of existing therapies / Jiannis Mountzios and Jean-Charles Soria -- Signal transduction inhibitors, HER family, EGFR inhibition, and clinical achievements / Giuseppe Giaccone and Paolo Zucali -- HER2 inhibition and clinical achievements / Toru Mukohara and Pasi A. Janne -- Pan-HER inhibitors / Gerard Milano -- Inhibiting the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway / Janet E. Dancey -- Farnesyl transferase inhibitors in cancer: promise, but limited proof / Laura Fanucchi, Michael P. Fanucchi, and Fadlo R. Khuri -- Protein Kinase C inhibitors in the treatment of non-small cell lung cancer / Yun Oh. [et al.] -- Signal transduction inhibitors: PDGFR and c-KIT inhibitors / Jean-Yves Blay. [et al.] -- The insulin-like growth factor 1 receptor : a target for cancer treatment / Yungan Tao, Jean Bourhis, and Eric Deutsch -- Aurora kinase inhibitors / Mitesh J. Borad, Steven L. Warner, and Daniel D. von Hoff -- Apoptosis modulators : p53 targeting / Sunil Chada. [et al.] -- Survivin / Dario C. Altieri -- TRAIL modulators / C.H. Mom. [et al.] -- VEGF targeting / Lee M. Ellis -- Targeting angiogenesis with oral agents / Benjamin Besse and Jean-Pierre Armand -- Endothelial cell propagation targteing / Gordon C. Tucker -- HIF-1 inhibitors / Giovanni Melillo -- Antivascular agents / Jane Robertson -- Matrix metalloproteinases / Stephane Vignot and Jean-Philippe Sapno -- Src inhibitors / Francisco Cruzalegui -- Telomerase and Telomere interacting agents / Jean-Francoi Riou. [et al.] -- Targeting Hsp90 : the cancer super-chaperone / Paul Workman and Swee Sharp.